Last reviewed · How we verify
CCRF Consulting Co., Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Heparin or Bivalirudin | Heparin or Bivalirudin | marketed | Anticoagulant | Thrombin (Factor IIa) and Factor Xa (heparin); Thrombin (Factor IIa) (bivalirudin) | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Beijing Anzhen Hospital · 1 shared drug class
- Beijing Chao Yang Hospital · 1 shared drug class
- Beijing Suncadia Pharmaceuticals Co., Ltd · 1 shared drug class
- Boston Scientific Corporation · 1 shared drug class
- Deutsches Herzzentrum Muenchen · 1 shared drug class
- Faculty Hospital Kralovske Vinohrady · 1 shared drug class
- Anemia Working Group Romania · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for CCRF Consulting Co., Ltd.:
- CCRF Consulting Co., Ltd. pipeline updates — RSS
- CCRF Consulting Co., Ltd. pipeline updates — Atom
- CCRF Consulting Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). CCRF Consulting Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ccrf-consulting-co-ltd. Accessed 2026-05-17.